Jonathan Moens is a former intern at Spectrum and a graduate student at New York University’s Science, Health and Environmental Reporting Program. He studied philosophy and neuroscience as an undergraduate student at University College London in the United Kingdom. He received an M.Sc. in brain and mind sciences at University College London and École Normale Supérieure in Paris, France, specializing in cognitive neuroscience. He previously worked as a research assistant at the Neurospin laboratory in Paris and the Center for the Neuroscience of the Senses in London.
Jonathan Moens
From this contributor
Autism comorbidities reflect racial, ethnic disparities
Autistic people from historically marginalized races and ethnicities are more likely than their white peers to be diagnosed with accompanying health conditions.
Autism comorbidities reflect racial, ethnic disparities
By
Jonathan Moens
19 January 2022 | 2 min read
By the Numbers: Autism in translation, rising prevalence figures, intelligence quotients
In this edition of By the Numbers, we discuss how translation alters a screening tool’s accuracy, the closing racial gap in autism prevalence numbers, and the preponderance of autism without intellectual disability.
By the Numbers: Autism in translation, rising prevalence figures, intelligence quotients
By
Peter Hess, Niko McCarty, Jonathan Moens
21 December 2021 | 1 min read
Autism without intellectual impairments more common than previously reported
Almost 60 percent of autistic people may have an average or above-average intelligence quotient, according to a new longitudinal study.
Autism without intellectual impairments more common than previously reported
By
Jonathan Moens
1 December 2021 | 2 min read
Rethinking autism assessments in the time of COVID-19: Q&A with Bishop, Zwaigenbaum
Moving most clinical assessments online during the coronavirus pandemic has created a digital divide while closing some geographical ones, say Somer Bishop and Lonnie Zwaigenbaum.
Rethinking autism assessments in the time of COVID-19: Q&A with Bishop, Zwaigenbaum
By
Jonathan Moens
2 November 2021 | 7 min read
Disruptions to brain’s ‘thermostat’ may underpin autism traits
Mounting evidence suggests that autism often involves upsets in homeostatic plasticity, a set of processes neurons use to stabilize their activity. These disruptions result from a range of autism-linked mutations and may help to explain the condition’s famed heterogeneity.
Disruptions to brain’s ‘thermostat’ may underpin autism traits
By
Jonathan Moens
18 August 2021 | 7 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read